161 related articles for article (PubMed ID: 34891121)
1. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.
Scuteri D; Rombolà L; Hamamura K; Sakurada T; Watanabe C; Sakurada S; Guida F; Boccella S; Maione S; Gallo Afflitto G; Nucci C; Tonin P; Bagetta G; Corasaniti MT
Biomed Pharmacother; 2022 Feb; 146():112505. PubMed ID: 34891121
[TBL] [Abstract][Full Text] [Related]
2. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
[TBL] [Abstract][Full Text] [Related]
3. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.
Lötsch J; Weyer-Menkhoff I; Tegeder I
Eur J Pain; 2018 Mar; 22(3):471-484. PubMed ID: 29160600
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and CB
Toguri JT; Leishman E; Szczesniak AM; Laprairie RB; Oehler O; Straiker AJ; Kelly MEM; Bradshaw HB
Prostaglandins Other Lipid Mediat; 2018 Nov; 139():54-62. PubMed ID: 30232034
[TBL] [Abstract][Full Text] [Related]
5. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
Thapa D; Cairns EA; Szczesniak AM; Kulkarni PM; Straiker AJ; Thakur GA; Kelly MEM
Molecules; 2020 Jan; 25(2):. PubMed ID: 31968549
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
9. Approved cannabinoids for medical purposes - Comparative systematic review and meta-analysis for sleep and appetite.
Spanagel R; Bilbao A
Neuropharmacology; 2021 Sep; 196():108680. PubMed ID: 34181977
[TBL] [Abstract][Full Text] [Related]
10. The Cannabinoids Δ
Thapa D; Cairns EA; Szczesniak AM; Toguri JT; Caldwell MD; Kelly MEM
Cannabis Cannabinoid Res; 2018; 3(1):11-20. PubMed ID: 29450258
[No Abstract] [Full Text] [Related]
11. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy.
Szczesniak AM; Porter RF; Toguri JT; Borowska-Fielding J; Gebremeskel S; Siwakoti A; Johnston B; Lehmann C; Kelly ME
Neuropharmacology; 2017 Feb; 113(Pt B):627-638. PubMed ID: 27569993
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
Toth CC; Jedrzejewski NM; Ellis CL; Frey WH
Mol Pain; 2010 Mar; 6():16. PubMed ID: 20236533
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids and Pain: Sites and Mechanisms of Action.
Starowicz K; Finn DP
Adv Pharmacol; 2017; 80():437-475. PubMed ID: 28826543
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.
Hashiesh HM; Jha NK; Sharma C; Gupta PK; Jha SK; Patil CR; Goyal SN; Ojha SK
Eur J Pharmacol; 2021 Oct; 909():174398. PubMed ID: 34332924
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis.
Toguri JT; Lehmann C; Laprairie RB; Szczesniak AM; Zhou J; Denovan-Wright EM; Kelly ME
Br J Pharmacol; 2014 Mar; 171(6):1448-61. PubMed ID: 24308861
[TBL] [Abstract][Full Text] [Related]
17. Antiallodynic Effects of Cannabinoid Receptor 2 (CB
Sheng WS; Chauhan P; Hu S; Prasad S; Lokensgard JR
Pain Res Manag; 2019; 2019():1260353. PubMed ID: 31354896
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid-induced changes in respiration of brain mitochondria.
Fišar Z; Singh N; Hroudová J
Toxicol Lett; 2014 Nov; 231(1):62-71. PubMed ID: 25195527
[TBL] [Abstract][Full Text] [Related]
19. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
20. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
